Drug intelligence / Profile preview

BLI-1007

Development stage: Preclinical
Lead developer: BioLite
Modality: Small Molecules
Administration: Oral

Overview

BLI-1007 is a pure natural compound developed by BioLite, Inc. It is an orally administered small molecule drug that has demonstrated the ability to inhibit pro-inflammatory cytokines Tumor necrosis factor alpha (TNF-α), Interleukin 1 beta, and Interleukin 6 in animal studies. These actions are associated with the prevention and relief of arthritis symptoms. The drug is currently in the preclinical stage of development for immune system diseases, particularly rheumatoid arthritis. Preclinical studies were suspended due to unpromising results.

Targets

IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on BLI-1007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLI-1007.

Explore the full profile